- Home
- AHG vs TMCI Comparison
AHG vs TMCI Comparison
Compare AHG & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- TMCI
- Stock Information
- Founded
- AHG 2013
- TMCI 2014
- Country
- AHG China
- TMCI United States
- Employees
- AHG N/A
- TMCI N/A
- Industry
- AHG Business Services
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AHG Consumer Discretionary
- TMCI Health Care
- Exchange
- AHG Nasdaq
- TMCI Nasdaq
- Market Cap
- AHG 502.5M
- TMCI 516.6M
- IPO Year
- AHG N/A
- TMCI 2021
- Fundamental
- Price
- AHG $0.92
- TMCI $6.99
- Analyst Decision
- AHG
- TMCI Hold
- Analyst Count
- AHG 0
- TMCI 8
- Target Price
- AHG N/A
- TMCI $9.00
- AVG Volume (30 Days)
- AHG 25.0K
- TMCI 396.8K
- Earning Date
- AHG 04-21-2025
- TMCI 05-06-2025
- Dividend Yield
- AHG N/A
- TMCI N/A
- EPS Growth
- AHG N/A
- TMCI N/A
- EPS
- AHG N/A
- TMCI N/A
- Revenue
- AHG $8,454,946.00
- TMCI $209,357,000.00
- Revenue This Year
- AHG N/A
- TMCI $10.85
- Revenue Next Year
- AHG N/A
- TMCI $10.07
- P/E Ratio
- AHG N/A
- TMCI N/A
- Revenue Growth
- AHG 281.19
- TMCI 11.88
- 52 Week Low
- AHG $0.60
- TMCI $3.92
- 52 Week High
- AHG $2.35
- TMCI $12.65
- Technical
- Relative Strength Index (RSI)
- AHG 29.66
- TMCI 31.00
- Support Level
- AHG $0.83
- TMCI $6.66
- Resistance Level
- AHG $1.05
- TMCI $8.13
- Average True Range (ATR)
- AHG 0.10
- TMCI 0.56
- MACD
- AHG -0.03
- TMCI -0.10
- Stochastic Oscillator
- AHG 20.27
- TMCI 14.93
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.